Arrow Therapeutics Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 58

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $150M

Arrow Therapeutics General Information

Description

Developer of anti-viral drugs and therapies. The company focuses on developing anti-infective drugs which includes novel antibiotics, antivirals and antifungals for conditions such as hepatitis C, providing healthcare professionals with drugs for viral diseases.

Contact Information

Formerly Known As
Gac No.111 Limited, Gac No.111
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 7 Trinity Street
  • London SE1 1DB
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Acquirer
Corporate Office
  • 7 Trinity Street
  • London SE1 1DB
  • England, United Kingdom

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Arrow Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 01-Feb-2007 $150M Completed Generating Revenue
4. Later Stage VC 02-May-2006 Completed Generating Revenue
3. Early Stage VC (Series B) 01-Dec-2003 Completed Generating Revenue
2. Early Stage VC 06-Jul-2000 $16.8M $18.4M Completed Product Development
1. Seed Round 01-Jan-1999 $1.67M $1.67M Completed Startup
To view Arrow Therapeutics’s complete valuation and funding history, request access »

Arrow Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B2 Preferred
To view Arrow Therapeutics’s complete cap table history, request access »

Arrow Therapeutics Patents

Arrow Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2011151651-A1 Benzodiazepine compounds useful for the treatment of hepatitis c Inactive 03-Jun-2010
WO-2011151652-A1 Benzodiazepine compounds useful for the treatment of hepatitis c Inactive 03-Jun-2010
WO-2011027156-A1 Benzodiazepine derivatives for treating hepatitis c infection Inactive 03-Sep-2009
US-20110059043-A1 Chemical compounds Inactive 03-Sep-2009
WO-2010103306-A1 Benzimidazole derivatives and their use as antivaral agents Inactive 10-Mar-2009 C07D403/06
To view Arrow Therapeutics’s complete patent history, request access »

Arrow Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Arrow Therapeutics Former Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
3i Group PE/Buyout Minority
Alta Partners Venture Capital Minority
Atlas Venture Venture Capital Minority
Gimv PE/Buyout Minority
ITX (US) Corporation Minority
You’re viewing 5 of 13 investors. Get the full list »

Arrow Therapeutics FAQs

  • When was Arrow Therapeutics founded?

    Arrow Therapeutics was founded in 1998.

  • Where is Arrow Therapeutics headquartered?

    Arrow Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Arrow Therapeutics?

    Arrow Therapeutics has 58 total employees.

  • What industry is Arrow Therapeutics in?

    Arrow Therapeutics’s primary industry is Drug Discovery.

  • Is Arrow Therapeutics a private or public company?

    Arrow Therapeutics is a Private company.

  • What is the current valuation of Arrow Therapeutics?

    The current valuation of Arrow Therapeutics is .

  • What is Arrow Therapeutics’s current revenue?

    The current revenue for Arrow Therapeutics is .

  • How much funding has Arrow Therapeutics raised over time?

    Arrow Therapeutics has raised $73.1M.

  • Who are Arrow Therapeutics’s investors?

    3i Group, Alta Partners, Atlas Venture, Gimv, and ITX (US) are 5 of 13 investors who have invested in Arrow Therapeutics.

  • When was Arrow Therapeutics acquired?

    Arrow Therapeutics was acquired on 01-Feb-2007.

  • Who acquired Arrow Therapeutics?

    Arrow Therapeutics was acquired by AstraZeneca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process